Healthcare Strategy Partners (HSP)

Healthcare Strategy Partners (HSP) is a boutique consulting firm specializing in evidence-based strategic consulting exclusively for the biopharmaceutical industry. The firm operates from offices in Boston, Princeton, and Washington, DC, focusing on product and portfolio lifecycle decisions for pharma companies.

HSP's consulting approach centers on integrating evidence across clinical development, medical affairs, market access, and digital health disciplines. The firm offers three core service lines: evidence-based consulting, strategic market research, and data structuring/analysis. Their team brings cross-functional expertise combining quantitative analytical capabilities with qualitative research methods to support commercial decision-making.

The leadership team includes four senior consultants with expertise spanning pharmaceutical strategy and market research. HSP positions itself as providing what they term "the unfettered truth" through rigorous evidence integration and stakeholder analysis to accelerate client decision-making processes.

Choose HSP when you need strategic consulting that bridges clinical evidence, medical strategy, and commercial considerations for pharmaceutical products. Their boutique model suits companies seeking senior-level attention and cross-functional expertise rather than large consulting firm resources.

Expect a evidence-driven approach that integrates multiple stakeholder perspectives to inform product and portfolio decisions. The firm's focus on "unfettered truth" suggests direct, data-backed recommendations rather than purely consensus-driven consulting.

HSP operates exclusively within the pharmaceutical and biotechnology sector of healthcare. Their services address the unique challenges of drug development and commercialization, including clinical evidence generation, medical strategy, regulatory considerations, and payer market access. The firm's expertise spans the entire pharmaceutical product lifecycle from development through commercialization and lifecycle management.

Mid-sized to large pharmaceutical and biotechnology companies navigating complex product development and commercialization decisions. Organizations that value evidence synthesis across multiple functions and need strategic guidance on portfolio prioritization, market access strategy, or lifecycle management challenges.